EPFL-founded tissue analysis technology developer Lunaphore has now raised $37.3m in all after a series C round led by medical products firm PHC Holdings.
Lunaphore, a Switzerland-based cancer research and diagnostics spinout of École Polytechnique Fédérale de Lausanne, yesterday revealed it had raised an initial CHF23m ($23.6m) in series C funding led by healthcare group PHC Holdings.
The transaction, completed on January 15, also feature venture capital firm Redalpine Venture Partners, investment firm Alpana Ventures and investment group Occident.
Founded in 2014, Lunaphore has developed a human tissue analysis system for cancer research and pathological studies.
The spinout’s flagship product, LabSat Frozen, is able to run immunohistochemistry tests – a process of selectively identifying antigens in cells – in just 12 minutes in an automated and reproducible manner.
The series C funding will allow Lunaphore to increase next-generation product development, as well as facilitate an entry into the US and ramp up operations in Europe.
James Post, president of Epredia, a precision cancer diagnostics subsidiary of PHC, has joined…
